Glycomics Firm Sialix Developing Auto Antibody-Based Tests for Breast, Colon, Prostate Cancers
April 29, 2011
Glycomics Firm Sialix Developing Auto Antibody-Based Tests for Breast, Colon, Prostate Cancers
The company, which has licensed intellectual property related to use of the auto-antibodies from UCSD, aims to develop the diagnostics first as CLIA-based tests and ultimately in a microarray format available to physicians.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
April 22, 2011 / ProteoMonitor - Lung Cancer Study Highlights Current Limitations of MALDI Mass Spec
July 22, 2011 / ProteoMonitor - Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test
April 15, 2011 / ProteoMonitor - NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor - TGen's Center for Proteomics Named a Waters Center of Innovation
August 26, 2011 / ProteoMonitor